PMS2 and neoplasm: Tumors with MLH1/PMS2 loss (23.8% of all tumors in our sample) and high-grade endometrioid adenocarcinomas (13.5% of all endometrioid adenocarcinomas in our sample) were more likely to express PD-L1 in tumor cells.